Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2

Molecular Immunology

Volumn 45, Issue 13, 2008, Pages 3661-3670

  Katsara, Maria ^a,b   Yuriev, Elizabeth ^c   Ramsland, Paul A ^a   Deraos, George ^b   Tselios, Theodore ^b   Matsoukas, John ^b   Apostolopoulos, Vasso ^a  

^a BURNET INSTITUTE   (Australia)

^b Section of Organic Chemistry   (Greece)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Binding motif; EAE; H2 As; Mannan; MBP; Modeling; MS; Vaccine

Indexed keywords

CD4 ANTIGEN; HLA A ANTIGEN; MANNAN; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[83-99]; T LYMPHOCYTE RECEPTOR; YTTRIUM; YTTRIUM 91; MANNOSE; MUTANT PROTEIN; MYELIN BASIC PROTEIN 83 99; MYELIN BASIC PROTEIN 83-99; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CHEMICAL REACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG STRUCTURE; FEMALE; HYDROGEN BOND; IMMUNE RESPONSE; IMMUNOTHERAPY; MANNOSYLATION; MOLECULAR INTERACTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SPLEEN CELL; STRUCTURE ANALYSIS; SWISS JAMES LAMBERT MOUSE; TH1 CELL; TH2 CELL; VAN DER WAALS INTERACTION; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CROSS REACTION; DRUG SCREENING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE STRAIN; PHYSIOLOGY; PROTEIN PROCESSING;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CELLS, CULTURED; CROSS REACTIONS; DRUG EVALUATION, PRECLINICAL; FEMALE; LYMPHOCYTE ACTIVATION; MANNANS; MANNOSE; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; MUTANT PROTEINS; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TH1 CELLS; TH2 CELLS;

EID: 46749145677     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.04.024     Document Type: Article

References (53)

1. Acres B., Apostolopoulos V., Balloul J.M., Wreschner D., Xing P.X., Ali-Hadji D., Bizouarne N., Kieny M.P., and McKenzie I.F. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 48 (2000) 588-594
2. Apostolopoulos V., Pietersz G.A., Loveland B.E., Sandrin M.S., and McKenzie I.F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10128-10132
3. Apostolopoulos V., Pietersz G.A., and McKenzie I.F. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14 (1996) 930-938
4. Apostolopoulos V., Karanikas V., Haurum J.S., and McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol. 159 (1997) 5211-5218
5. Apostolopoulos V., Pietersz G.A., Gordon S., Martinez-Pomares L., and McKenzie I.F. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 30 (2000) 1714-1723
6. Apostolopoulos V., Barnes N., Pietersz G.A., and McKenzie I.F. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine 18 (2000) 3174-3184
7. Bankovich A.J., Girvin A.T., Moesta A.K., and Garcia K.C. Peptide register shifting within the MHC groove: theory becomes reality. Mol. Immunol. 40 (2004) 1033-1039
8. Barlos K., and Gatos D. 9-Fluorenylmethyloxycarbonyl/tbutyl-based convergent protein synthesis. Biopolymers 51 (1999) 266-278
9. Barlos K., Gatos D., and Koutsogianni S. Fmoc/Trt-amino acids: comparison to Fmoc/tBu-amino acids in peptide synthesis. J. Pept. Res. 51 (1998) 194-200
10. Bieganowska K.D., Ausubel L.J., Modabber Y., Slovik E., Messersmith W., and Hafler D.A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185 (1997) 1585-1594
11. Corper A.L., Stratmann T., Apostolopoulos V., Scott C.A., Garcia K.C., Kang A.S., Wilson I.A., and Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288 (2000) 505-511
12. Davis W.C., Konzek R.L., Haas K., Estes D.M., Hamilton M.J., Call D.R., Apostolopoulos V., and McKenzie I.F. Use of the mannan receptor to selectively target vaccine antigens for processing and antigen presentation through the MHC class I and class II pathways. Ann. N. Y. Acad. Sci. 969 (2002) 119-125
13. Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., and Pieters J. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 27 (1997) 2417-2425
14. Fremont D.H., Monnaie D., Nelson C.A., Hendrickson W.A., and Unanue E.R. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. Immunity 8 (1998) 305-317
15. Gauthier L., Smith K.J., Pyrdol J., Kalandadze A., Strominger J.L., Wiley D.C., and Wucherpfennig K.W. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11828-11833
16. He X.L., Radu C., Sidney J., Sette A., Ward E.S., and Garcia K.C. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au. Immunity 17 (2002) 83-94
17. Kalbus M., Fleckenstein B.T., Offenhausser M., Bluggel M., Melms A., Meyer H.E., Rammensee H.G., Martin R., Jung G., and Sommer N. Ligand motif of the autoimmune disease-associated mouse MHC class II molecule H2-A(s). Eur. J. Immunol. 31 (2001) 551-562
18. Karanikas V., Hwang L.A., Pearson J., Ong C.S., Apostolopoulos V., Vaughan H., Xing P.X., Jamieson G., Pietersz G., Tait B., Broadbent R., Thynne G., and McKenzie I.F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100 (1997) 2783-2792
19. Katsara M., Tselios T., Deraos S., Deraos G., Matsoukas M., Lazoura E., Matsoukas J., and Apostolopoulos V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem. 13 (2006) 2221-2232
20. Katsara, M., Deraos, G., Tselios, T., Matsoukas, J., Apostolopoulos, V., 2008. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 modulate immune responses in SJL/J mice. J. Med. Chem., in press.
21. Krissinel E., and Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372 (2007) 774-797
22. Krogsgaard M., Wucherpfennig K.W., Cannella B., Hansen B.E., Svejgaard A., Pyrdol J., Ditzel H., Raine C., Engberg J., and Fugger L. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191 (2000) 1395-1412
23. Kuchroo V.K., Greer J.M., Kaul D., Ishioka G., Franco A., Sette A., Sobel R.A., and Lees M.B. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153 (1994) 3326-3336
24. Latek R.R., Suri A., Petzold S.J., Nelson C.A., Kanagawa O., Unanue E.R., and Fremont D.H. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 12 (2000) 699-710
25. Lees C.J., Apostolopoulos V., Acres B., Ong C.S., Popovski V., and McKenzie I.F. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunol. Immunother. 48 (2000) 644-652
26. Lees C.J., Apostolopoulos V., Acres B., Ramshaw I., Ramsay A., Ong C.S., and McKenzie I.F. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine 19 (2000) 158-162
27. Liu X., Dai S., Crawford F., Fruge R., Marrack P., and Kappler J. Alternate interactions define the binding of peptides to the MHC molecule IA(b). Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8820-8825
28. Lofthouse S.A., Apostolopoulos V., Pietersz G.A., Li W., and McKenzie I.F. Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. Vaccine 15 (1997) 1586-1593
29. Martin R., Howell M.D., Jaraquemada D., Flerlage M., Richert J., Brostoff S., Long E.O., McFarlin D.E., and McFarland H.F. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173 (1991) 19-24
30. Matsoukas J., Apostolopoulos V., Kalbacher H., Papini A.M., Tselios T., Chantzantoni K., Biagioli T., Lolli F., Deraos S., Papathanassopoulos P., Mavromoustakos T., Probert L., and Mouzaki A. Enhanced stability and biological properties of myelin basic protein epitope 87-99 cyclic mimics render them a potentially new class of immunomodulators. J. Med. Chem. 10 (2005) 1470-1480
31. Moreau T., Coles A., Wing M., Isaacs J., Hale G., Waldmann H., and Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119 Pt 1 (1996) 225-237
32. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., and Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
33. Reizis B., Eisenstein M., Mor F., and Cohen I.R. The peptide-binding strategy of the MHC class II I-A molecules. Immunol. Today 19 (1998) 212-216
34. Rudensky A., Preston-Hurlburt P., al-Ramadi B.K., Rothbard J., and Janeway Jr. C.A. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 359 (1992) 429-431
35. Scott C.A., Peterson P.A., Teyton L., and Wilson I.A. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 8 (1998) 319-329
36. Sheng K.C., Pouniotis D.S., Wright M.D., Tang C.K., Lazoura E., Pietersz G.A., and Apostolopoulos V. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118 (2006) 372-383
37. Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., and Wucherpfennig K.W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188 (1998) 1511-1520
38. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.A., and Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79 (1997) 54-61
39. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 (1996) 299-302
40. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., Mulder A.A., van der Heiden A.N., Scheidegger D., Oomen L.C., Ottenhoff T.H., Tulp A., Neefjes J.J., and Koning F. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 27 (1997) 2426-2435
41. Tselios T.V., Probert L., Daliani I., Matsoukas E., Troganis A., Gerothanassis I., Mavromoustakos T., Moore G., and Matsoukas J. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem. 42 (1999) 1170-1177
42. Tselios T.V., Apostolopoulos V., Daliani I., Deraos S., Grdadolnik S., Mavromoustakos T., Melachrinou M., Thymianou S., Probert L., Mouzaki A., and Matsoukas J. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J. Med. Chem. 45 (2002) 275-283
43. Tselios T.V., Lamari F.N., Karathanasopoulou I., Katsara M., Apostolopoulos V., Pietersz G.A., Matsoukas J.M., and Karamanos N.K. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal. Biochem. 13 (2005) 2221-2232
44. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., Hochberger M., Albert E.D., and Adorini L. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91 (1993) 616-628
45. Vaughan H.A., Ho D.W., Karanikas V.A., Ong C.S., Hwang L.A., Pearson J.M., McKenzie I.F., and Pietersz G.A. Induction of humoral and cellular responses in cynomolgus monkeys immunized with mannan-human MUC1 conjugates. Vaccine 17 (1999) 2740-2752
46. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8 (1995) 127-134
47. Wang J.H., Meijers R., Xiong Y., Liu J.H., Sakihama T., Zhang R., Joachimiak A., and Reinherz E.L. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10799-10804
48. Willenborg D.O., and Staykova M.A. Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis. Adv. Exp. Med. Biol. 520 (2003) 96-119
49. Wucherpfennig K.W., Hafler D.A., and Strominger J.L. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8896-8900
50. Zamvil S.S., and Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8 (1990) 579-621
51. Zamvil S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R., and Steinman L. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317 (1985) 355-358
52. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., and Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179 (1994) 973-984
53. Zhu Y., Rudensky A.Y., Corper A.L., Teyton L., and Wilson I.A. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. J. Mol. Biol. 326 (2003) 1157-1174